Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -13.03% and Operating profit at -36.96% over the last 5 years
2
The company has declared negative results in Mar'2025 after 2 consecutive positive quarters
3
With ROE of 6.50%, it has a fair valuation with a 2.03 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 19,569 Million (Large Cap)
31.00
NA
0.89%
0.06
5.19%
3.43
Revenue and Profits:
Net Sales:
1,000 Million
(Quarterly Results - Mar 2026)
Net Profit:
58 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
29.19%
0%
29.19%
6 Months
-5.13%
0%
-5.13%
1 Year
383.72%
0%
383.72%
2 Years
319.66%
0%
319.66%
3 Years
174.83%
0%
174.83%
4 Years
182.61%
0%
182.61%
5 Years
98.24%
0%
98.24%
Zhende Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-13.03%
EBIT Growth (5y)
-36.96%
EBIT to Interest (avg)
50.41
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.67
Tax Ratio
17.09%
Dividend Payout Ratio
44.94%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
36.27%
ROE (avg)
21.96%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
2.03
EV to EBIT
36.68
EV to EBITDA
20.28
EV to Capital Employed
2.02
EV to Sales
2.68
PEG Ratio
0.21
Dividend Yield
1.52%
ROCE (Latest)
5.51%
ROE (Latest)
6.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,000.40
1,145.30
-12.65%
Operating Profit (PBDIT) excl Other Income
60.60
143.20
-57.68%
Interest
8.10
6.50
24.62%
Exceptional Items
11.50
-2.10
647.62%
Consolidate Net Profit
57.60
56.60
1.77%
Operating Profit Margin (Excl OI)
60.50%
57.10%
0.34%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -12.65% vs 5.65% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 1.77% vs -29.16% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,306.30
4,247.90
1.37%
Operating Profit (PBDIT) excl Other Income
603.90
602.60
0.22%
Interest
35.60
31.60
12.66%
Exceptional Items
3.10
-21.10
114.69%
Consolidate Net Profit
267.10
397.20
-32.75%
Operating Profit Margin (Excl OI)
70.90%
83.50%
-1.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1.37% vs 3.27% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -32.75% vs 86.13% in Dec 2024
About Zhende Medical Co., Ltd. 
Zhende Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






